|Bid||11.01 x 100|
|Ask||11.40 x 600|
|Day's Range||10.80 - 11.22|
|52 Week Range||8.36 - 27.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.17|
NEW YORK, NY / ACCESSWIRE / March 2, 2018 / Markets continued to slide Thursday after President Trump announced that tariffs on steel and aluminum imports were on the way. The Dow Jones Industrial Average ...
On a per-share basis, the Seattle-based company said it had a loss of 34 cents. Losses, adjusted for non-recurring costs, came to 25 cents per share. The drug developer posted revenue of $13.8 million ...
Omeros Corporation , a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Omeros Corporation (NASDAQ: OMER ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018, at 4:30 PM Eastern Time. ...
Omeros Corporation today announced that the company will issue its fourth quarter and year-end 2017 financial results for the period ended December 31, 2017, on Thursday, March 1, 2018, after the market closes.
Omeros Corporation today announced new results from the company’s ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy .
Shares of drug maker Omeros Corporation (NASDAQ:OMER) are down 17% as of 3:53 p.m. EST today. In its report, FourWorld notes that Medicare, describing Omidria as a "nice-to-have" but not a "need-to-have" product, ended "pass-through" reimbursement for the drug as of January 1.
Omeros Corp. is the latest short target for FourWorld Capital Management LLC, as the investment adviser issues a new report on the drugmaker with a price target of $4.00, suggesting a more than 70 percent ...
NEW YORK, Feb. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bank ...
Omeros Corporation announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products issued a positive opinion on Omeros’ application for orphan drug designation of OMS721 in the treatment of primary Immunoglobulin A nephropathy . OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 , the effector enzyme of the lectin ...
Omeros shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 85.
NEW YORK, NY / ACCESSWIRE / January 5, 2018 / Shares of HTG Molecular Diagnostics were on a rampage on Thursday after the company released preliminary financial results. Omeros Corporation traded fairly ...
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
Omeros Corporation (NASDAQ:OMER), a pharmaceuticals company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGM. With manyRead More...
This morning, the drug maker announced that it has reached an agreement with the FDA that available data from OMS721 supports the prospect for benefit in IgA nephropathy (IgAN) patients. Following the approval of the Phase 3 trial protocol, patient enrollment is expected to begin early next month. Omeros CEO Gregory Demopulos commented, "We’re pleased to have received agreement from FDA for our OMS721 Phase 3 protocol in IgA nephropathy [...] Final preparations to begin the trial can now be completed and enrollment is expected to open in early February.
Omeros Corporation today announced that it has reached agreement with the US Food and Drug Administration on Omeros’ protocol for its Phase 3 clinical trial evaluating OMS721 in patients with IgA nephropathy .
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Omeros Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Omeros Corp. – Pfizer Inc., BioTime, Inc., Acura Pharmaceuticals, Inc., Akorn, Inc., DURECT Corporation and Pain Therapeutics, Inc. (PFE-US, BTX-US, ACUR-US, AKRX-US, DRRX-US and PTIE-US) that have also reported ... Read more (Read more...)
Omeros (OMER) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.